Journal article
Role of AV nodal ablation in cardiac resynchronization in patients with coexistent atrial fibrillation and heart failure: A systematic review
AN Ganesan, AG Brooks, KC Roberts-Thomson, DH Lau, JM Kalman, P Sanders
Journal of the American College of Cardiology | ELSEVIER SCIENCE INC | Published : 2012
Abstract
Objectives: The aim of this study was to systematically review the medical literature to evaluate the impact of AV nodal ablation in patients with heart failure and coexistent atrial fibrillation (AF) receiving cardiac resynchronization therapy (CRT). Background: CRT has a substantial evidence base in patients in sinus rhythm with significant systolic dysfunction, symptomatic heart failure, and prolonged QRS duration. The role of CRT is less well established in AF patients with coexistent heart failure. AV nodal ablation has recently been suggested to improve outcomes in this group. Methods: Electronic databases and reference lists through September 15, 2010, were searched. Two reviewers ind..
View full abstractGrants
Funding Acknowledgements
From the *Centre for Heart Rhythm Disorders, University of Adelaide and Royal Adelaide Hospital, Adelaide, Australia; and the dagger Department of Cardiology, Royal Melbourne Hospital and the Department of Medicine, University of Melbourne, Melbourne, Australia. Dr. Ganesan is supported by a Cardiovascular Lipid Research Grant from Pfizer Australia. Drs. Brooks, Roberts-Thomson, and Sanders are supported by the National Heart Foundation of Australia. Dr. Lau is supported by a Postdoctoral Fellowship from the National Health and Medical Research Council of Australia. Dr. Roberts-Thomson has served on the advisory board of St. Jude Medical. Dr. Sanders has received lecture fees from St. Jude Medical, Bard Electrophysiology, Biosense-Webster, Medtronic, and Merck; research funding from St. Jude Medical, Bard Electrophysiology, Biosense-Webster, and Medtronic; and is on the advisory board for St. Jude Medical, Bard Electrophysiology, Biosense-Webster, Medtronic, and Merck. Dr. Kalman has received unrestricted research grants from St. Jude Medical and Medtronic.